Skip to main content
Fig. 2 | Annals of Intensive Care

Fig. 2

From: Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?

Fig. 2

Frequency of immune-related adverse events. a Toxicity related to anti-PD-1/PDL-1i; b toxicity related to CTLA-4i. The size of the circles reflects the incidence of toxicity: blue, toxicity of any grade; red, grade III/IV toxicity. None of the circles describe toxicity related to CTLA-4i associated with PD-1/PDL-1i inhibitors (the incidence of combined treatments is higher than the toxicity of each inhibitor). Incidence data from [8] and [47]

Back to article page